Cosmo Pharmaceuticals N.V. (FRA:C43)

Market Cap	1.41B +61.3%
Revenue (ttm)	104.17M -61.0%
Net Income	-3.61M
EPS	-0.23
Shares Out	n/a
PE Ratio	n/a
Forward PE	873.45
Dividend	2.10 (2.43%)
Ex-Dividend Date	Apr 24, 2026

Volume	n/a
Average Volume	100
Open	88.00
Previous Close	86.50
Day's Range	88.00 - 88.00
52-Week Range	47.80 - 141.00
Beta	n/a
RSI	33.14
Earnings Date	Mar 9, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cor...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 325
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C43